Oxaliplatin Accord (Oxaliplatin)

Oxaliplatin Accord is used in colorectal cancer treatment protocols that target DNA replication pathways.

• Colorectal cancer: Enhances tumor response when combined with fluoropyrimidine‑based regimens.
• Gastric cancer: Contributes to tumor shrinkage as part of combination chemotherapy.
• Pancreatic cancer: Used off‑label in some regimens to improve response rates.

• Oxaliplatin exerts its antitumor activity by forming platinum‑DNA adducts that distort the DNA helix, inhibiting replication and transcription. The resulting DNA damage triggers apoptosis in rapidly dividing cancer cells, particularly those reliant on the mismatch repair pathway.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Peripheral neuropathy: Tingling or numbness, often dose‑related.
• Nausea and vomiting: Frequently experienced during or after infusion.
• Diarrhea: May range from mild to moderate severity.
• Fatigue: Generalised tiredness common during treatment cycles.
• Thrombocytopenia: Reduced platelet count observed in blood tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: Including anaphylaxis, requiring immediate medical attention.
• Acute hemolytic anemia: Rapid destruction of red blood cells.
• Persistent neutropenia: Prolonged low neutrophil count increasing infection risk.
• Pulmonary toxicity: Interstitial lung disease or pneumonitis.
• Cardiac arrhythmias: Uncommon but potentially life‑threatening rhythm disturbances.

When handling Oxaliplatin Accord, clinicians should observe several safety measures.

• Renal function monitoring: Assess baseline and periodic creatinine levels.
• Hepatic function monitoring: Check liver enzymes before each cycle.
• Neurotoxicity vigilance: Evaluate sensory symptoms before each infusion.
• Hematologic surveillance: Perform complete blood counts regularly.
• Premedication: Consider anti‑emetic prophylaxis to reduce nausea.
• Store at ambient temperature: Keep vials in original packaging, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, altering efficacy or safety.

Major Interactions (Avoid)

• Aminoglycoside antibiotics: May increase nephrotoxic risk.
• High‑dose vitamin C: Can reduce platinum‑DNA binding effectiveness.

Moderate Interactions (Monitor Closely)

• Anticoagulants anticoagulants: May heighten bleeding risk due to thrombocytopenia.
• NSAIDs: Potentially exacerbate renal impairment.
• Other neurotoxic agents: May compound peripheral neuropathy.
• Strong CYP3A4 inducers: May affect plasma levels of co‑administered drugs.
• Proton pump inhibitors: May alter gastric pH and affect oral supportive care agents.